FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common adverse reactions reported for Zinbryta were rash, increased alanine aminotransferase (ALT), depression, nasopharyngitis, upper respiratory tract infection, influenza, oropharyngeal pain, and lymphadenopathy.
Croatian: Najčešće nuspojave prijavljene pri liječenju Zinbrytom bile su osip, povišene razine alanin aminotransferaze (ALT), depresija, nazofaringitis, infekcija gornjih dišnih putova, gripa, orofaringealna bol i limfadenopatija.
English: • However, if it is more than 2 weeks from your missed dose, skip the missed dose and take your next dose on your usual day.
Croatian: • Međutim, ako je prošlo više od 2 tjedna od propuštene doze, preskočite propuštenu dozu i primijenite sljedeću dozu na Vaš uobičajen dan.
English: Animal studies do not indicate direct or indirect harmful effects with respect to reprotoxicity (see section 5.3).
Croatian: Ispitivanja na životinjama ne ukazuju na izravan ili neizravan štetan učinak na reprodukciju (vidjeti dio 5.3).
English: Zinbryta has no or negligible influence on the ability to drive and use machines.
Croatian: Zinbryta ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Toxic skin eruption
Croatian: Toksična kožna erupcija
English: You may be tested for TB before starting Zinbryta and monitored during treatment.
Croatian: Možda ćete se morati testirati na tuberkulozu prije početka liječenja Zinbrytom i biti praćeni tijekom liječenja.
English: As an IgG1 monoclonal antibody, daclizumab is expected to undergo catabolism to peptides and amino acids in the same manner as endogenous IgG.
Croatian: Budući da je IgG1 monoklonsko protutijelo, za daklizumab se očekuje katabolizam na peptide i aminokiseline na isti način kao i za endogeni IgG.
English: The majority of patients with infections continued on treatment with Zinbryta.
Croatian: Većina bolesnika s infekcijama nastavila je liječenje Zinbrytom.
English: Mutagenesis Genotoxicity studies have not been conducted.
Croatian: Mutageneza Nisu provedena ispitivanja genotoksičnosti.
English: *Hazard ratio for the risk of relapse #MRI analyses used evaluable dataset for each endpoint; T1 Gd-enhancing: MRI intensive population
Croatian: *Omjer hazarda za rizik od relapsa # Analiza MR koristila je skup podataka koji su se mogli ocijeniti za svaki ishod; T1 pojačane gadolinijem: MR intenzivna populacija
English: Table 5: DECIDE study clinical and MRI results (96 to 144 weeks) (Values refer to results at 96 weeks, unless otherwise indicated.)
Croatian: Tablica 5: Kliničko ispitivanje DECIDE i MR rezultati (od 96. do 144. tjedna) (Ako nije drugačije naznačeno, vrijednosti se odnose na 96. tjedan)
English: Your doctor or nurse should train you to give yourself the injections.
Croatian: Liječnik ili medicinska sestra će Vas naučiti kako si davati injekcije.
English: What you need to know before you use Zinbryta
Croatian: Što morate znati prije nego počnete primjenjivati Zinbrytu
English: A multipack of three packs of one syringe/pen is also available.
Croatian: Također je dostupno višestruko pakiranje od tri pakiranja s jednom štrcaljkom/brizgalicom.
English: The dose of Zinbryta is 150 mg every month.
Croatian: Doza Zinbryte je 150 mg svaki mjesec.
English: Step 6: Give the injection a.
Croatian: 6. korak: Primjena injekcije a.
English: Discontinuation of Zinbryta due to infections was <1%.
Croatian: Prekid liječenja Zinbrytom zbog infekcija bio je <1%.
English: Most patients had mild elevations that were below or up to 3 x ULN and resolved spontaneously.
Croatian: U većine bolesnika povišenja su bila blaga, do 3 x GGN ili manje, i nestala su spontano.
English: o If Zinbryta has been outside of the refrigerator for more than a total of 30 days or if you are not sure how long Zinbryta has been at room temperature, throw the syringe/pen away (see section 7, Instructions for injecting Zinbryta).
Croatian: o Ako je Zinbryta bila izvan hladnjaka dulje od ukupno 30 dana ili ako niste sigurni koliko je dugo Zinbryta bila na sobnoj temperaturi, bacite štrcaljku/brizgalicu (vidjeti dio 7, Upute za injiciranje Zinbryte).
English: Rhinitis*
Croatian: Rinitis*
English: Possible liver problems
Croatian: Mogući problemi s jetrom
English: • Each pen can be used once only.
Croatian: Jedna brizgalica može se upotrijebiti samo jedanput.
English: Zinbryta 150 mg p-value
Croatian: Zinbryta 150 mg p-vrijednost
English: Check the injection status window.
Croatian: Provjerite prozorčić stanja injekcije.
English: Table 3: Study design and baseline characteristics for SELECT study and DECIDE study Study name
Croatian: Tablica 3: Dizajn ispitivanja i početne značajke ispitivanja SELECT i DECIDE
English: After the needle is in, let go of your skin
Croatian: Nakon što je igla ubodena, otpustite kožu.
English: In clinical studies, serum transaminase elevations occurred at any time during treatment and up to 6 months after the last dose of Zinbryta.
Croatian: U kliničkim ispitivanjima povišenja razina serumskih transaminaza pojavila su se u bilo kojem trenutku tijekom liječenja i do 6 mjeseci nakon zadnje doze Zinbryte.
English: The absolute bioavailability of daclizumab 150 mg subcutaneously administered was approximately 90% based on a cross-study population pharmacokinetic analysis of subcutaneous and intravenous dosing.
Croatian: Apsolutna bioraspoloživost supkutano primijenjenog daklizumaba od 150 mg bila je otprilike 90% na osnovi analize populacijske farmakokinetike između ispitivanja supkutanog i intravenskog doziranja.
English: Detailed instructions for injecting Zinbryta are given in section 7, Instructions for injecting Zinbryta.
Croatian: Detaljne upute za injiciranje Zinbryte nalaze se u dijelu 7, Upute za injiciranje Zinbryte.
English: Based on the cross-study population pharmacokinetic analysis, the clearance of daclizumab is 0.212 L/day with a terminal half-life value of approximately 21 days.
Croatian: Na temelju analize populacijske farmakokinetike između ispitivanja, klirens daklizumaba iznosi 0,212 l/dan s vrijednošću terminalnog poluvijeka od oko 21 dana.
English: Your doctor will help you decide whether you should stop breast-feeding, or stop using Zinbryta.
Croatian: Vaš liječnik će vam pomoći odlučiti da li biste trebali prestati dojiti ili prestati koristiti Zinbrytu.
English: Note: Do not touch or blow on this area before giving your injection.
Croatian: Napomena: Nemojte dirati ili puhati na to mjesto prije davanja injekcije.
English: • Before you use the Zinbryta pre-filled syringe for the first time, your doctor or nurse should show you or your carer how to prepare and inject the Zinbryta pre-filled syringe.
Croatian: • Prije nego što prvi put upotrijebite Zinbryta napunjenu štrcaljku, liječnik ili medicinska sestra trebaju pokazati Vama ili Vašem njegovatelju kako pripremiti i injicirati Zinbrytu u napunjenoj štrcaljki.
English: Treatment-emergent anti-drug antibodies and neutralising antibodies were observed in 19% (175/913) and 8% (71/913) of study patients, respectively.
Croatian: Nastajanje protutijela na lijek i neutralizirajućih protutijela tijekom liječenja zabilježeno je u 19% (175/913) odnosno 8% (71/913) bolesnika u ispitivanju.
English: • the pen has been dropped or is visibly damaged.
Croatian: • brizgalica pala ili je vidljivo oštećena.
English: Seborrhoeic dermatitis†
Croatian: Seboroični dermatitis†
English: Note: After the pen has been removed from the injection site, the needle cover will lock to protect against needle injury.
Croatian: Napomena: Kada brizgalicu maknete s mjesta injekcije, pokrov igle će se zablokirati kako bi se spriječile ozljede iglom.
English: In clinical studies, Zinbryta increased the incidence of lymphadenopathy, with onset occurring throughout the treatment period.
Croatian: U kliničkim ispitivanjima Zinbryta je povećala incidenciju limfadenopatije, uz nastup koji se pojavljivao tijekom cijelog razdoblja liječenja.
English: • The need to screen for hepatitis B and C prior to treatment initiation and to recommend patients who test positive for HBV or HCV infection to consult with a physician with expertise in the treatment of those conditions.
Croatian: • potrebu testova na hepatitis B i C prije početka liječenja i potrebu da se bolesnicima koji su pozitivni na infekciju HBV-om ili HCV-om preporuči zatražiti savjet liječnika specijalista za liječenje tih bolesti
English: Innovation House 70 Norden Road
Croatian: 70 Norden Road
English: Treatment-emergent anti-drug antibodies and neutralising antibodies responses predominantly occurred during the first year of treatment and their frequency declined with continued Zinbryta treatment.
Croatian: Odgovori s protutijelima na lijek i neutralizirajućim protutijelima nastalima liječenjem uglavnom su se pojavili tijekom prve godine liječenja i njihova učestalost se smanjila sa nastavkom liječenja Zinbrytom.
English: Do not use Zinbryta - if you have previously had a serious allergic reaction to daclizumab, or any of the other ingredients of this medicine listed in section 6.
Croatian: Nemojte primjenjivati Zinbrytu - ako ste imali ozbiljnu alergijsku reakciju na daklizumab ili neki drugi sastojak ovog lijeka naveden u dijelu 6. - ako imate tegobe s jetrom.
English: • diarrhoea that does not go away
Croatian: • proljev koji ne prolazi
English: Autoimmune haemolytic anaemia
Croatian: Autoimuna hemolitična anemija
English: Carcinogenicity studies with daclizumab have not been conducted.
Croatian: Nisu provedena ispitivanja kancerogenosti s daklizumabom.
English: Wipe your skin with an alcohol wipe.
Croatian: Obrišite kožu vatom natopljenom alkoholom.
English: • Each Zinbryta pre-filled syringe can be used once only.
Croatian: • Jedna Zinbryta napunjena štrcaljka se može koristiti samo jedanput.
English: Based on the cross-study population pharmacokinetic analysis, the steady-state volume of distribution of daclizumab is 6.34 L in a patient with a body weight of 68 kg (approximate median of evaluated patients).
Croatian: Na temelju analize populacijske farmakokinetike između ispitivanja, volumen distribucije daklizumaba u stanju dinamičke ravnoteže je 6,34 l u bolesnika s tjelesnom težinom od 68 kg (približan medijan procijenjenih bolesnika).
English: These findings (dry, red raised patchy areas of the skin, as compared to controls, that correlated microscopically with acanthosis/hyperkeratosis and sub-acute to chronic inflammation) were characterised predominantly as mild to moderate, with one case assessed as severe.
Croatian: Ti nalazi (suhe, crvene uzdignute mrlje na koži, u usporedbi s kontrolama, koje koreliraju mikroskopski s akantozom/hiperkeratozom i subakutnim do kroničnim upalama) uglavnom su karakterizirani kao blagi do umjereni, s jednim slučajem ocijenjenim kao teškim.
English: Zinbryta is not expected to affect your ability to drive and use machines.
Croatian: Ne očekuje se da će Zinbryta utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: Due to the risk of hepatic injury, the use of Zinbryta is restricted (see section 4.1).
Croatian: Zbog rizika od oštećenja jetre primjena Zinbryte je ograničena (vidjeti dio 4.1).
English: • irritability, getting upset easily
Croatian: • razdražljivost, tendencija lakom uzrujavanju
English: • You should hold the pen over your injection site at a 90o angle.
Croatian: • Brizgalicu treba držati iznad mjesta injiciranja pod kutom od 90o.
English: In addition, an increase in CD56bright NK cells and a decrease in regulatory T-cells (defined as CD4+CD127lowFoxP3+ T-cells) was observed within 2 weeks after the first dose, with a sustained 5-fold increase in CD56bright NK cells above baseline and an approximately 60% decrease in regulatory T-cells in the treatment phase, with a return to baseline levels approximately 20-24 weeks after the last dose.
Croatian: Osim toga, porast broja CD56bright NK stanica i smanjenje broja regulacijskih T-stanica (definiranih kao CD4+CD127lowFoxP3+T-stanice) uočeni su unutar 2 tjedna nakon prve doze, s održanim peterostrukim povećanjem broja CD56bright NK stanica iznad početne vrijednosti i približnim smanjenjem od 60% u broju regulacijskih T-stanica u fazi liječenja, uz povratak na početne vrijednosti približno 20-24 tjedna nakon zadnje doze.
English: The most commonly reported adverse reactions leading to discontinuation in patients treated with Zinbryta were hepatic reactions, including elevations of serum transaminases (5%), and cutaneous reactions (4%) (see section 4.4).
Croatian: Najčešće prijavljene nuspojave koje vode do trajnog prekida liječenja u bolesnika liječenih Zinbrytom bile su jetrene nuspojave, uključujući povišenje razine serumskih transaminaza (5%), te kožne reakcije (4%) (vidjeti dio 4.4).
English: Zinbryta is contraindicated in patients with pre-existing hepatic impairment (see sections 4.3 and 4.4).
Croatian: Zinbryta je kontraindicirana u bolesnika s postojećim oštećenjem jetre (vidjeti dijelove 4.3 i 4.4).
English: Daclizumab is a humanised IgG1 monoclonal antibody that binds to CD25 (IL-2Rα), and prevents IL-2 binding to CD25.
Croatian: Daklizumab je humanizirano IgG1 monoklonsko protutijelo koje se veže na CD25 (IL-2Rα), te sprječava vezanje IL-2 na CD25.
English: The needle cover will extend to cover the needle and will lock (See Figure I).
Croatian: Pokrov igle će se proširiti tako da pokriva iglu i blokirati u tom položaju (vidjeti sliku I).
English: Caution!
Croatian: Oprez!
English: Tonsillitis†
Croatian: Tonzilitis†
English: Contents of the pack and other information Instructions for injecting Zinbryta
Croatian: Sadržaj pakiranja i druge informacije Upute za injiciranje Zinbryte
English: Pack sizes: Each pack contains one pre-filled glass syringe/pre-filled pen with an attached needle, ready to inject.
Croatian: Veličine pakiranja: Jedno pakiranje sadrži jednu napunjenu staklenu štrcaljku/napunjenu brizgalicu s pričvršćenom iglom, spremnu za injiciranje.
English: Based on the cross-study population pharmacokinetic analysis, body weight accounted for less than 40% of the inter-patient variability in daclizumab clearance.
Croatian: Na temelju analize populacijske farmakokinetike između ispitivanja, tjelesna težina bila je uzrok za manje od 40% varijabilnosti između bolesnika u klirensu daklizumaba.
English: • the syringe/pen is cracked or broken
Croatian: • je štrcaljka/brizgalica napuknuta ili slomljena
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Zinbryta in one or more subsets of the paediatric population in treatment of multiple sclerosis (see section 4.2 for information on paediatric use).
Croatian: Pedijatrijska populacija Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Zinbryta u svim podskupinama pedijatrijske populacije u liječenju multiple skleroze (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: After your injection After Use - Parts of your Zinbryta Pen (see Figure K):
Croatian: Nakon injekcije Nakon primjene - dijelovi Zinbryta brizgalice (vidjeti sliku K):
English: With your other hand, firmly grasp the needle cover and pull it straight off the needle (See Figure G).
Croatian: Drugom rukom čvrsto uhvatite pokrov igle i povucite ga ravno van (vidjeti sliku G).
English: Step 8: Check to make sure you have received your full dose of Zinbryta (see Figure J).
Croatian: 8. korak: Kako provjeriti da ste primili punu dozu Zinbryte (vidjeti sliku J) a.
English: • The importance of detecting signs and symptoms which might indicate hepatic injury, and if any of these occur, to promptly contact their physician;
Croatian: • navesti važnost otkrivanja znakova i simptoma koji mogu ukazivati na oštećenje jetre, i ako se bilo što od toga pojavi, odmah se obratiti liječniku
English: Anaemia*
Croatian: Anemija*
English: Fulminant hepatitis
Croatian: Fulminantni hepatitis
English: Daclizumab modulates IL-2 signalling by blocking CD25-dependent, highaffinity IL-2 receptor signalling, resulting in higher levels of IL-2 available for signalling through the intermediate-affinity IL-2 receptor.
Croatian: Daklizumab modulira signaliziranje IL-2 blokiranjem signaliziranja putem receptora visokog afiniteta za IL-2 ovisnog o CD25, što dovodi do viših razina IL-2 na raspolaganju za signaliziranje putem receptora intermedijarnog afiniteta za IL-2.
English: It should include the following elements:
Croatian: Edukacijski materijal uključuje sljedeće:
English: Continue to hold the pen firmly down on your injection site until the clicking sounds have stopped (see Figure H).
Croatian: Nastavite držati brizgalicu pritisnutu na mjestu injiciranja sve dok zvuk klikanja ne prestane (vidjeti sliku H).
English: The study designs and baseline characteristics are presented in Table 3.
Croatian: Dizajn ispitivanja i početne značajke prikazane su u tablici 3.
English: • Patients who had failed to respond to a full and adequate course (at least 1 year) of prior DMT treatment, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2 hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years.
Croatian: • Bolesnici koji nisu odgovorili na potpun i adekvatni tijek (od najmanje 1 godine) prethodnog liječenja terapijom koja modificira tijek bolesti, imali su najmanje 1 relaps u protekloj godini dok su primali terapiju, i najmanje 9 hiperintenivnih lezija na kranijalnoj MR T2-mjerenoj snimci ili barem 1 leziju imbibiranu
English: Do not share Zinbryta pre-filled syringe with anyone else.
Croatian: Nemojte dijeliti Zinbryta napunjenu štrcaljku ni s kim drugim.
English: If you do not hear clicking sounds or you do not see green ticks in the injection status window after attempting to inject, the pen may have locked and you may not have received your injection.
Croatian: Ako ne čujete zvuk klikanja ili ne vidite zelene kvačice u prozorčiću stanja injekcije kada ste pokušali injicirati,
English: The clinical relevance of microglial aggregates is unknown, however no deleterious neurologic effects attributed to the microscopic change have been observed in monkeys.
Croatian: Klinički značaj agregata mikroglije je nepoznat, međutim, u majmuna nije bilo zapaženih štetnih neuroloških učinka koji se mogu pripisati mikroskopskoj promjeni.
English: Step 2: Collect your supplies and wash your hands a. Find a well-lit area and a clean, flat surface, like a table, and collect all the supplies you will need to give yourself, or to receive, an injection.
Croatian: Nađite dobro osvijetljenu, čistu i ravnu površinu za rad, poput stola i prikupite sav pribor koji Vam je potreban za samostalno davanje injekcije ili da primite injekciju.
English: Do not take the Zinbryta pre-filled syringe out of the injection site until you have pushed the plunger all the way down.
Croatian: Nemojte izvaditi Zinbryta napunjenu štrcaljku iz mjesta injekcije sve dok niste pritisnuli klip do kraja.
English: 150 mg Prefilled Syringe Figure A
Croatian: 150 mg napunjena štrcaljka Slika A
English: • Patient Card;
Croatian: • Karticu za bolesnika
English: In two 9 month studies conducted in cynomolgus monkeys daclizumab was subcutaneously administered at bi-weekly doses of 10-200 mg/kg.
Croatian: U dva 9-mjesečna ispitivanja provedena u makaki majmuna, daklizumab je primijenjen supkutano u dvotjednim dozama od 10-200 mg/kg.
English: Figure 2: Proportion of patients with 24 week confirmed disability (DECIDE study)
Croatian: Slika 2: Udio bolesnika s potvrđenom onesposobljenosti tijekom 24 tjedna (ispitivanje
English: Treatment initiation is not recommended in patients with ALT or AST ≥ 2 times the upper limit of normal (ULN) and is contraindicated in patients with pre-existing hepatic impairment (see section 4.3).
Croatian: Ne preporučuje se započeti liječenje u bolesnika s vrijednostima ALT ili AST ≥ 2 puta iznad gornje granice normale (GGN), a liječenje je kontraindicirano u bolesnika s postojećim oštećenjem jetre (vidjeti dio 4.3).
English: The Acknowledgment Form aims at providing information on the risk of serious hepatic injury to patients.
Croatian: Obrazac potvrde o upoznatosti s rizikom namijenjen je kako bi se bolesnike obavijestilo o riziku od ozbiljnog oštećenja jetre.
English: Colourless to slightly yellow, clear to slightly opalescent liquid with pH 6.
Croatian: Bezbojna do blago žuta, bistra do blago opalescentna tekućina s pH 6.
English: Subgroup analyses of the SELECT and DECIDE studies demonstrated a consistent effect of Zinbryta compared to placebo and interferon beta-1a (intramuscular) across subgroups defined by demographic and MS disease characteristics.
Croatian: Analize podskupina u ispitivanjima SELECT i DECIDE pokazale su dosljedan učinak Zinbryte u usporedbi s placebom i interferonom beta-1a (intramuskularno) za sve podskupine definirane demografskim značajkama i značajkama MS bolesti.
English: Do not inject directly into your belly button.
Croatian: Nemojte injicirati izravno u pupak.
English: • Before you use the pen for the first time, your doctor or nurse should show you or your carer how to prepare and inject the pen.
Croatian: • Prije nego što prvi put upotrijebite brizgalicu, liječnik ili medicinska sestra trebaju pokazati Vama ili Vašem njegovatelju kako pripremiti i injicirati lijek brizgalicom.
English: Preclinical safety studies were conducted in cynomolgus monkeys due to species specificity of daclizumab binding only to human or primate CD25.
Croatian: 5.3 Neklinički podaci o sigurnosti primjene Neklinička ispitivanja sigurnosti su provedena u makaki majmuna zbog specifičnosti vezanja daklizumaba samo na ljudski ili primatski CD25.
English: Daclizumab clearance in patients who developed neutralising antibodies was, on average, 19% higher (see section 4.8 Immunogenicity).
Croatian: Klirens daklizumaba u bolesnika koji su razvili neutralizirajuća protutijela bio je u prosjeku 19% viši (vidjeti dio 4.8 Imunogenost).
English: Within the studied regimens of daclizumab 150 mg and 300 mg administered subcutaneous every 4 weeks in MS patients, there was no clear relationship between daclizumab exposure and clinical efficacy endpoints (ARR, T2 lesions and Gd-enhancing lesions) or safety endpoints of interest (serious infection status, moderate or severe cutaneous adverse reaction, and AST/ALT > 5 times the ULN).
Croatian: Unutar ispitivanih režima daklizumaba od 150 mg i 300 mg primijenjenih supkutano svaka 4 tjedna u bolesnika s MS-om, nije bilo jasnog odnosa između izloženosti daklizumabu i ishoda kliničke djelotvornosti (godišnje stope relapsa, lezije na T2-mjerenoj snimci i lezije imbibirane gadolinijem) ili ishoda sigurnosti od interesa (stanje ozbiljne infekcije, umjerene ili teške kožne nuspojave, i AST/ALT > 5 puta GGN).
English: Patients treated with Zinbryta should be advised to report any symptoms of new or worsening depression, and/or suicidal ideation immediately to the prescribing physician.
Croatian: Bolesnike liječene Zinbrytom treba savjetovati da odmah prijave liječniku propisivaču bilo kakve simptome nove ili pogoršane depresije i/ili suicidalne ideje.
English: • If needed, apply a gauze pad, adhesive bandage or plaster to the injection site.
Croatian: • Ako je potrebno, primijenite jastučić gaze ili flaster na mjesto injiciranja.
English: Viral infection
Croatian: Virusne infekcije
English: Zinbryta is injected under the skin (subcutaneously) into your thigh, stomach or back of your upper arm.
Croatian: Zinbryta se injicira pod kožu (supkutano) u bedra, trbuh ili stražnji dio nadlaktice.
English: Re-capping could cause the pen to lock.
Croatian: Ponovno stavljanje zatvarača moglo bi zakočiti brizgalicu.
English: Do not use external heat sources, such as hot water, to warm the pen.
Croatian: Nemojte koristiti vanjske izvore topline, kao što je vruća voda, da zagrijete brizgalicu.
English: Step 3: Choose and clean your injection site
Croatian: 3. korak: Odaberite i očistite mjesto za injiciranje
English: You should see green ticks.
Croatian: Trebali biste vidjeti zelene kvačice.
English: Hepatic Risk Management Guide for Physicians, Patient Card and Acknowledgment Form
Croatian: Vodič za liječnike o zbrinjavanju rizika za jetru, Kartica za bolesnika i Obrazac potvrde o upoznatosti s rizikom